Trial · NCT07521046
Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis
NCT07521046, Phase 1, Recruiting, University of Utah
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis. Trials, record NCT07521046. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07521046
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis
- NCT number
- NCT07521046
- Status
- Recruiting
- Phases
- Phase 1
- Enrollment
- 15 participants, estimated
- Lead sponsor
- University of Utah
- Conditions
- Myelofibrosis
- Interventions
- ropeginterferon alfa- 2b, Ruxolitinib
- First posted
- 2026-04-09
- Last updated
- 2026-10-19
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by type | 2 years | To assess the safety and tolerability of ropeginterferon alfa- 2b add-on to ruxolitinib in the study population. |
| Primary | The frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by severity (as defined by the NIH CTCAE, version 6.0). | 2 years | To assess the safety and tolerability of ropeginterferon alfa- 2b add-on to ruxolitinib in the study population. |
| Primary | The frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by seriousness. | 2 years | To assess the safety and tolerability of ropeginterferon alfa- 2b add-on to ruxolitinib in the study population. |
| Primary | The frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by duration. | 2 years | To assess the safety and tolerability of ropeginterferon alfa- 2b add-on to ruxolitinib in the study population. |
| Primary | The frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by the relationship to study treatment. | 2 years | To assess the safety and tolerability of ropeginterferon alfa- 2b add-on to ruxolitinib in the study population. |
| Secondary | The proportion of subjects who achieve >50% reduction in JAK2 V617F mutation burden. | 2 years | To assess the incidence of patients who achieve \>50% reduction in JAK2 V617F mutation burden. |
| Secondary | Change in JAK2, CALR, MPL mutations allelic burden. | 2 years | To assess the rate of reduction of JAK2, CALR, MPL mutations allelic burden. |
| Secondary | The proportion of subjects who achieve a 25% decrease in spleen volume by 24 weeks from initiation of combination treatment. | 24 weeks | To assess the rate of 25% spleen volume reduction at 24 weeks of the combination (Abdominal MRI will be done for spleen size measurement). |
| Secondary | Change in quality of life Myeloproliferative Neoplasm (MPN) Symptom Questionnaire from baseline and throughout treatment. | 2 years | To assess the change in the quality of life MPN Symptom Questionnaire score. The MPN Symptom questionnaire consists of 10 questions asking patients to rate their symptoms on a scale of 1 to 10, with 0 being no symptoms and 10 being the worst symptoms. |
| Secondary | The proportion of subjects who progress to blastic phase and secondary acute myeloid leukemia at 2 years post-treatment. | 2 years | To assess the rate of blastic transformation. |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07521046
GET https://conductscience.org/api/trials/v1/NCT07521046/registered